Search reports, ask a question, or jump to a page.
The problem
Intervention: Maternal RSV vaccination (14+ days before delivery) and nirsevimab (monoclonal antibody) administration to infants
Who it was tested with: Infants younger than 8 months at clinical sites in New York during 2023-2024 and 2024-2025 RSV seasons.
The same group is measured before the intervention and again afterwards, with a baseline and an endline and sometimes a midline. Change is visible, but other causes cannot be ruled out.
"This cohort study was performed at clinical sites affiliated with a quaternary care hospital in New York, New York, from October 1, 2023, to March 31, 2024, and October 1, 2024, to March 31, 2025. Participants included infants younger than 8 months who had at least 1 clinical encounter during the 2023-2024 and 2024-2025 RSV seasons." The study measured actual receipt of two RSV prevention strategies across two consecutive seasons in the same population, allowing comparison of uptake trends and identification of disparities.
Single-site study in a quaternary care setting with predominantly private insurance and term infants; results may not represent less affluent communities or hospitals with different patient populations; study does not assess clinical outcomes or effectiveness in preventing RSV disease
Across countries and designs
1 study · 1 country
